[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630176":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":10,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":10,"maxAge":10,"enrollmentInfo":32,"targetDuration":10,"studyType":35,"phases":10,"briefSummary":36,"conditions":37,"keywords":39,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"lutetium (177Lu) vipivotide tetraxetan",null,"Patients with metastatic prostate cancer who are treated with lutetium (177Lu) vipivotide tetraxetan over a five-year followup period",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100630176",false,"NCT07484269","PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan","Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)","PULSE","Inclusion criteria:\n\nAge ≥ 18 years at index date\n\n* Diagnosis of mPC\n* PSMA positive\n* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date\n\nExclusion criterion:\n\n• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)","MALE",{"count":33,"type":34},753,"ESTIMATED","OBSERVATIONAL","The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer",[38],"Metastatic Prostate Cancer",[40,41],"Prostate cancer","metastatic prostate cancer","NOT_YET_RECRUITING","2026-03-16",{"date":45,"type":46},"2026-03-20","ACTUAL",{"date":48,"type":34},"2026-08-01",{"date":50,"type":34},"2031-07-31",{"name":14,"class":6}]